Us Bancorp \De\ Taysha Gene Therapies, Inc. Transaction History
Us Bancorp \De\
- $75.6 Billion
- Q4 2024
A detailed history of Us Bancorp \De\ transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 728 shares of TSHA stock, worth $1,193. This represents 0.0% of its overall portfolio holdings.
Number of Shares
728
Previous 860
15.35%
Holding current value
$1,193
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding TSHA
# of Institutions
130Shares Held
151MCall Options Held
48KPut Options Held
7.8K-
Avoro Capital Advisors LLC New York, NY20MShares$32.8 Million0.5% of portfolio
-
Morgan Stanley New York, NY17.6MShares$28.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$19.3 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$17.8 Million0.3% of portfolio
-
Octagon Capital Advisors LP New York, NY10.5MShares$17.1 Million4.03% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $79.3M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...